Specialty Chemical Stock In Upper Circuit For 11th Continuous Session; 241% Rally YTD

One of the multibagger companies in the speciality chemical sector with multibagger YTD returns is Sudarshan Pharma Industries. Since the eleventh consecutive session, the stock has been in a steady upward trend, hitting the upper circuit. The Sudarshan Pharma Industries shares began on Thursday at Rs 274.50, the 5% upper circuit limit, indicating no sellers were present. The stock climbed 21.51% over the previous five sessions, 45.39% over the last month, and 287.44% over the last six months.
.

Sudarshan Pharma Industries Latest News

The significant rally in SPIL's stock price comes on the back of several strategic moves made by the company to expand its operations and strengthen its position in the pharmaceutical industry. One of the latest developments is the incorporation of its new subsidiary, Sudarshan Maven Pharma Private Limited (Sudarshan Maven), which was officially registered on August 27, 2024.

Sudarshan Pharma announced the formation of Sudarshan Maven, which will serve as a new subsidiary to further its growth in the pharmaceutical sector. According to an official exchange filing, the company has subscribed to 70% of the equity capital of Sudarshan Maven, amounting to 7,000 shares at a nominal value of Rs 10 each. The total equity share capital of Sudarshan Maven is Rs 25 lakh, divided into 2,50,000 shares of Rs 10 each.

Although Sudarshan Maven is a newly established entity with no turnover to report as of now, the move is seen as part of SPIL's broader strategy to diversify and strengthen its market presence. The company's proactive approach to expansion, particularly through new subsidiaries and acquisitions, has been instrumental in driving investor confidence, as evidenced by the stock's recent performance.

Sudarshan Pharma's recent incorporation of Sudarshan Maven follows a series of strategic growth initiatives. In August 2023, the company completed the acquisition of Ratna Lifesciences Pvt. Ltd., a move that further solidified its foothold in the pharmaceutical industry. The acquisition, valued at Rs 5.5 crore, was an all-cash deal, making Ratna Lifesciences a wholly-owned subsidiary of SPIL. This acquisition, finalized on August 30, 2023, highlighted SPIL's commitment to expanding its portfolio and tapping into new market segments.

Sudarshan Pharma Industries Shareholding Pattern

As of the March 2024 quarter, Sudarshan Pharma's shareholding pattern reveals that promoters hold a majority stake of 57.39%, while non-institutional investors own 41.21%. Foreign Institutional Investors (FIIs) own a minor 1.40% stake in the company. The solid backing of promoters and the increasing interest from non-institutional investors underscore the confidence in SPIL's long-term growth potential.

About Sudarshan Pharma Industries

Established in 2008, Sudarshan Pharma Industries Ltd operates as a contract producer of generic formulations, catering to various industries, including pharmaceuticals, specialty chemicals, bulk supplies, and intermediates. The company's product offerings encompass a wide range of Active Pharmaceutical Ingredients (APIs) and formulation generics, which are supplied to healthcare organizations and pharmaceutical companies. SPIL is also involved in sourcing and providing pharmaceuticals to different industries, bolstering its diverse revenue streams.

Additionally, SPIL markets its own line of branded products under the Vimac Healthcare division. The company currently has 96 products in this line, with 56 of them registered under the "R" trademark, further reinforcing its brand identity and market presence.